High Levels of Triggering Receptor Expressed in Myeloid Cells-Like Transcript-1 Positive, but Not Glycoprotein 1b+, Microparticles Are Associated With Poor Outcomes in Acute Respiratory Distress Syndrome.

Q4 Medicine
Critical care explorations Pub Date : 2024-06-27 eCollection Date: 2024-07-01 DOI:10.1097/CCE.0000000000001108
Angelia D Gibson, Zaida Bayrón-Marrero, Benjamin Nieves-Lopez, Gerónimo Maldonado-Martínez, A Valance Washington
{"title":"High Levels of Triggering Receptor Expressed in Myeloid Cells-Like Transcript-1 Positive, but Not Glycoprotein 1b+, Microparticles Are Associated With Poor Outcomes in Acute Respiratory Distress Syndrome.","authors":"Angelia D Gibson, Zaida Bayrón-Marrero, Benjamin Nieves-Lopez, Gerónimo Maldonado-Martínez, A Valance Washington","doi":"10.1097/CCE.0000000000001108","DOIUrl":null,"url":null,"abstract":"<p><strong>Objectives: </strong>To identify triggering receptor expressed in myeloid cells-like transcript-1 positive (TLT-1+) microparticles (MPs) and evaluate if their presence is associated with clinical outcomes and/or disease severity in acute respiratory distress syndrome (ARDS).</p><p><strong>Design: </strong>Retrospective cohort study.</p><p><strong>Setting: </strong>ARDS Network clinical trials.</p><p><strong>Patients: </strong>A total of 564 patients were diagnosed with ARDS.</p><p><strong>Interventions: </strong>None.</p><p><strong>Measurements and main results: </strong>Using flow cytometry, we demonstrated the presence of TLT-1+ platelet-derived microparticles (PMP) that bind fibrinogen in plasma samples from fresh donors. We retrospectively quantified TLT-1, glycoprotein (Gp) 1b, or αIIbβIIIa immunopositive microparticles in plasma samples from patients with ARDS enrolled in the ARMA, KARMA, and LARMA (Studies 01 and 03 lower versus higher tidal volume, ketoconazole treatment, and lisofylline treatment Clincial Trials) ARDS Network clinical trials and evaluated the relationship between these measures and clinical outcomes. No associations were found between Gp1b+ MPs and clinical outcomes for any of the cohorts. When stratified by quartile, associations were found for survival, ventilation-free breathing, and thrombocytopenia with αIIbβIIIa+ and TLT-1+ MPs (χ2p < 0.001). Notably, 63 of 64 patients in this study who failed to achieve unassisted breathing had TLT+ PMP in the 75th percentile. In all three cohorts, patients whose TLT+ MP counts were higher than the median had higher Acute Physiology and Chronic Health Evaluation III scores, were more likely to present with thrombocytopenia and were 3.7 times (p < 0.001) more likely to die than patients with lower TLT+ PMP after adjusting for other risk factors.</p><p><strong>Conclusions: </strong>Although both αIIbβIIIa+ and TLT+ microparticles (αIIbβIIIa, TLT-1) were associated with mortality, TLT-1+ MPs demonstrated stronger correlations with Acute Physiology and Chronic Health Evaluation III scores, unassisted breathing, and multiple system organ failure. These findings warrant further exploration of the mechanistic role of TLT-1+ PMP in ARDS or acute lung injury progression.</p>","PeriodicalId":93957,"journal":{"name":"Critical care explorations","volume":"6 7","pages":"e1108"},"PeriodicalIF":0.0000,"publicationDate":"2024-06-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11213581/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Critical care explorations","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1097/CCE.0000000000001108","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/7/1 0:00:00","PubModel":"eCollection","JCR":"Q4","JCRName":"Medicine","Score":null,"Total":0}
引用次数: 0

Abstract

Objectives: To identify triggering receptor expressed in myeloid cells-like transcript-1 positive (TLT-1+) microparticles (MPs) and evaluate if their presence is associated with clinical outcomes and/or disease severity in acute respiratory distress syndrome (ARDS).

Design: Retrospective cohort study.

Setting: ARDS Network clinical trials.

Patients: A total of 564 patients were diagnosed with ARDS.

Interventions: None.

Measurements and main results: Using flow cytometry, we demonstrated the presence of TLT-1+ platelet-derived microparticles (PMP) that bind fibrinogen in plasma samples from fresh donors. We retrospectively quantified TLT-1, glycoprotein (Gp) 1b, or αIIbβIIIa immunopositive microparticles in plasma samples from patients with ARDS enrolled in the ARMA, KARMA, and LARMA (Studies 01 and 03 lower versus higher tidal volume, ketoconazole treatment, and lisofylline treatment Clincial Trials) ARDS Network clinical trials and evaluated the relationship between these measures and clinical outcomes. No associations were found between Gp1b+ MPs and clinical outcomes for any of the cohorts. When stratified by quartile, associations were found for survival, ventilation-free breathing, and thrombocytopenia with αIIbβIIIa+ and TLT-1+ MPs (χ2p < 0.001). Notably, 63 of 64 patients in this study who failed to achieve unassisted breathing had TLT+ PMP in the 75th percentile. In all three cohorts, patients whose TLT+ MP counts were higher than the median had higher Acute Physiology and Chronic Health Evaluation III scores, were more likely to present with thrombocytopenia and were 3.7 times (p < 0.001) more likely to die than patients with lower TLT+ PMP after adjusting for other risk factors.

Conclusions: Although both αIIbβIIIa+ and TLT+ microparticles (αIIbβIIIa, TLT-1) were associated with mortality, TLT-1+ MPs demonstrated stronger correlations with Acute Physiology and Chronic Health Evaluation III scores, unassisted breathing, and multiple system organ failure. These findings warrant further exploration of the mechanistic role of TLT-1+ PMP in ARDS or acute lung injury progression.

髓系细胞样转录本-1 阳性而非糖蛋白 1b+ 微颗粒中表达的高水平触发受体与急性呼吸窘迫综合征的不良预后有关。
目的确定髓样细胞转录本-1阳性(TLT-1+)微颗粒(MPs)中表达的触发受体,并评估它们的存在是否与急性呼吸窘迫综合征(ARDS)的临床结果和/或疾病严重程度相关:设计:回顾性队列研究:背景:ARDS 网络临床试验:干预措施:无:测量和主要结果通过流式细胞术,我们证实了新鲜供体血浆样本中存在结合纤维蛋白原的 TLT-1+ 血小板衍生微颗粒 (PMP)。我们回顾性地量化了 ARMA、KARMA 和 LARMA(研究 01 和 03:较低潮气量与较高潮气量、酮康唑治疗和利索菲林治疗省级试验)ARDS 网络临床试验中 ARDS 患者血浆样本中的 TLT-1、糖蛋白(Gp)1b 或 αIIbβIIIa 免疫阳性微粒,并评估了这些指标与临床结果之间的关系。在所有队列中,均未发现 Gp1b+ MPs 与临床结果之间存在关联。当按四分位数分层时,发现存活率、无通气呼吸和血小板减少与 αIIbβIIIa+ 和 TLT-1+ MPs 有关(χ2p < 0.001)。值得注意的是,在这项研究中,64 名未能实现无助呼吸的患者中有 63 人的 TLT+ PMP 在第 75 百分位数。在所有三个队列中,TLT+ MP计数高于中位数的患者急性生理学和慢性健康评估 III 评分较高,更有可能出现血小板减少症,在调整其他风险因素后,其死亡几率是 TLT+ PMP 较低患者的 3.7 倍(p < 0.001):虽然αⅡbβⅢa+和TLT+微颗粒(αⅡbβⅢa,TLT-1)都与死亡率有关,但TLT-1+MPs与急性生理学和慢性健康评估III评分、无辅助呼吸和多系统器官衰竭有更强的相关性。这些发现值得进一步探讨 TLT-1+ PMP 在 ARDS 或急性肺损伤进展中的机理作用。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
CiteScore
5.70
自引率
0.00%
发文量
0
审稿时长
8 weeks
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信